ArticlePharmaceuticals (Basel, Switzerland)2022

MiR-486-5p Targets CD133+ Lung Cancer Stem Cells through the p85/AKT Pathway.

Massimo Moro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.